Ascentage Pharma Group International (AAPG) Non-Current Receivables: 2023-2024

  • Ascentage Pharma Group International's Non-Current Receivables rose 264.29% to $3.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was $3.6 million, marking a year-over-year increase of 264.29%. This contributed to the annual value of $3.6 million for FY2024, which is 257.56% up from last year.
  • Ascentage Pharma Group International's Non-Current Receivables amounted to $3.6 million in Q4 2024, which was up 264.29% from $979,434 recorded in Q4 2023.
  • Ascentage Pharma Group International's 5-year Non-Current Receivables high stood at $3.6 million for Q4 2024, and its period low was $979,434 during Q4 2023.
  • Its 2-year average for Non-Current Receivables is $2.3 million, with a median of $2.3 million in 2023.
  • Data for Ascentage Pharma Group International's Non-Current Receivables shows a peak YoY skyrocketed of 264.29% (in 2024) over the last 5 years.
  • Quarterly analysis of 2 years shows Ascentage Pharma Group International's Non-Current Receivables stood at $979,434 in 2023, then spiked by 264.29% to $3.6 million in 2024.